Deals in Depth: December 2009
Executive Summary
Astellas will be developing Ambit's FLT3 kinase blockers in the month's largest deal at $390 million. Sanofi-Aventis' move into the US OTC market was evident in its acquisition of Chattem for $2.1 billion. In one of the five biggest medical device acquisitions of 2009, Ethicon bought sinus surgical device company Acclarent for $785 million. Financing for biopharma companies increased dramatically to over $2 billion, most of which came from three $400 million-plus FOPOs. Device fundraising was down slightly in December, although diabetes management firm Intuity Medical impressed with its $64 million Series D round.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.